Clinical Trials and Clinical Research
Our dedicated Clinical Research Department offers innovative clinical research trials dedicated to fighting disease and improving the health and wellness of our patients.
Clinical trials include:
- Psoriasis
- Cellulite
- Rosacea
- Acne
- Vitiligo
- Double chin
- Hidradenitis Suppurativa
- Atopic Dermatitis (Eczema)
- Skin Cancer
- Alopecia Areata
- Actinic Keratosis
- Gorlin Syndrome
What our patients say
Why participate?
Clinical trials include:
- Access to the latest medical treatments
- No cost to enroll
- No insurance needed
- You may be eligible to receive reimbursement for time & travel
- Receive support from a dedicated team of dermatology professionals

World-class Leadership
Our Principal Investigators are award-winning dermatologists and are involved in every aspect of the patient visit
Featured Articles
Cutera, Inc. (Nasdaq: CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today announced that the 12-month clinical data related to AviClear, the first and only FDA-cleared energy-based device for the treatment of mild, moderate, and severe acne, was presented at the Annual Fall Clinical Dermatology Conference, which took place October 20-23 in Las Vegas, Nevada.
Current clinical studies show that after three 30-minute treatment sessions, 90% of patients had a visible improvement in their acne at 6 months.1 New 12-month clinical findings show this improvement increases to 92%,2 confirming the continual improvement of acne clearance and skin quality over time. Studies also demonstrate that three-fourths of patients showed a 2+ IGA score improvement and two-thirds of patients were assessed as clear or almost-clear 12 months after their final treatment session.3
Read More
A better understanding of the pathogenesis of eczema has brought new biologic agents and oral medications to market, which have proved effective in treating atopic dermatitis (AD), explained Jerry Bagel, MD, director of the Eczema Treatment Center of New Jersey.
However, despite the recent influx of new treatments, Bagel asserts the importance of reminding patients that AD is a chronic inflammatory disease. Remission is possible, but follow-up care is crucial.